NCT02487979 2022-01-18Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory OsteosarcomaNational Cancer Institute (NCI)Phase 2 Completed22 enrolled 15 charts
NCT02363283 2020-08-21Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal MelanomaNational Cancer Institute (NCI)Phase 2 Completed37 enrolled 12 charts